Pembrolizumab-induced cytokine release syndrome with severe encephalopathy in the setting of clear cell vaginal carcinoma: A case report

Samantha Metzger; Keely Ulmer; Emily K. Hill

doi:10.1016/j.gore.2024.101529

Back

Pembrolizumab-induced cytokine release syndrome with severe encephalopathy in the setting of clear cell vaginal carcinoma: A case report

Journal article

Open access

Peer reviewed

Pembrolizumab-induced cytokine release syndrome with severe encephalopathy in the setting of clear cell vaginal carcinoma: A case report

Samantha Metzger, Keely Ulmer and Emily K. Hill

Gynecologic oncology reports, Vol.56, 101529

12/2024

DOI: 10.1016/j.gore.2024.101529

PMCID: PMC11530849

PMID: 39494393

Files and links (1)

url

https://doi.org/10.1016/j.gore.2024.101529View

Published (Version of record) Open Access

Abstract

•Pembrolizumab is increasingly used in the treatment of gynecologic cancers and has a half-life of 26 days.•Cytokine release syndrome with severe encephalopathy is a rare immune mediated adverse effect.•Supportive care remains an important part of the treatment of immune-mediated toxicity, as it takes 5 half-lives to clear Pembrolizumab from the body.

Clear cell vaginal carcinoma

Encephalitis

Immune checkpoint inhibitor

Pembrolizumab

Details

Title: Subtitle: Pembrolizumab-induced cytokine release syndrome with severe encephalopathy in the setting of clear cell vaginal carcinoma: A case report
Creators: Samantha Metzger
Keely Ulmer
Emily K. Hill
Resource Type: Journal article
Publication Details: Gynecologic oncology reports, Vol.56, 101529
DOI: 10.1016/j.gore.2024.101529
PMID: 39494393
PMCID: PMC11530849
NLM abbreviation: Gynecol Oncol Rep
ISSN: 2352-5789
eISSN: 2352-5789
Publisher: Elsevier Inc
Grant note: Funding The authors declare that they have not received any funding for this report.
Language: English
Date published: 12/2024
Academic Unit: Epidemiology; Obstetrics and Gynecology
Record Identifier: 9984732542202771

Metrics

6 Record Views